Videx (Didanosine, ddI)
| Brand Name: |
Videx EC |
| Generic Name: |
Didanosine, ddI |
| Adult Single Dose: |
400 mg once daily for those who weigh at least 60 kg; 250 mg once daily if 25-59 kg; 200 mg once daily if 20-24 kg |
| Food & Liquid Restrictions: |
Take on an empty stomach |
| Drug Class: |
NRTI |
The Basics
- Didanosine (Videx, ddI) (January 19, 2013)
To read PDF, click here.
From AIDS InfoNet
- An Overview of Videx (Didanosine, ddI) (September 13, 2012)
From AIDSinfo
- Videx EC (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Patient Information About Videx (Didanosine, ddI) (PDF) (November 2011)
From Bristol-Myers Squibb Company
- Videx EC (Didanosine, ddI EC) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- ddI (Videx, didanosine) (August 15, 2006)
From AIDS Treatment Data Network
- Videx (Didanosine) (May 2005)
To read PDF, click here.
From The Center for AIDS
- Drug Interactions: Didanosine (August 2004)
From Project Inform
- New ddI Warning (October 2000)
In What's New, from Project Inform
- Twice-Daily ddI Recommended (Autumn 2000)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- ddI, d4T and Hydroxyurea Side Effect Warning! (April 2000)
In Project Inform Perspective, from Project Inform
- Updates: Pancreatitis Warning for Videx (Spring 2000)
In STEP Perspective, from Seattle Treatment Education Project
News
 AIDS Activist Allen Huff Dies of an HIV Drug Side Effect: A Blog Entry by Nelson Vergel (June 13, 2011)
"My friend, Allen Huff, died on Friday. He battled portal hypertension caused by Videx (ddI) and was not a candidate for surgery to repair the damage caused by that drug."
From TheBody.com
- Safety Risk Associated With HIV Drug Videx (February 2, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Videx EC/Videx (Didanosine) Label Change Reflects Potential for Serious Liver Disorder (January 29, 2010)
From U.S. Food and Drug Administration
- Important Changes to Videx (Didanosine) Labeling (June 19, 2009)
From U.S. Food and Drug Administration
- Videx EC Labeling Changes With Pediatric Dosing Information Added (September 30, 2008)
From U.S. Food and Drug Administration
- FDA Approves Generic Formulation of Didanosine (ddI) Delayed Release Capsules (December 3, 2004)
From AIDSinfo
- Warning on Two Specific 3-Drug Regimens: Viread + Videx + Either Sustiva or Viramune (November 23, 2004)
A brief comment on the recently issued warning that both regimens frequently fail.
In AIDS Treatment News, from AIDS Treatment News
- Thailand: Patients, Advocates Sue to Invalidate Videx EC Patent (October 10, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- New Safety Information for Videx (Didanosine, ddI) Used With Ribavirin (September 25, 2002)
From U.S. Food and Drug Administration
- ddI-Tenofovir Interaction Warning (PDF) (May 7, 2002)
From Bristol-Myers Squibb Company
VIEW ALL ARTICLES
Research
- Emtriva + Reyataz + Videx Not as Effective as Combivir + Sustiva in First-Line Therapy, Study Finds (May 28, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Abacavir, Didanosine Associated With Higher Heart Attack Risk, D:A:D Study Finds (February 5, 2008)
An interview with Jens Lundgren, M.D.
In 15th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Position Statement by the D:A:D Steering Committee (February 4, 2008)
A discussion of the significance of a study examining the association between use of abacavir, didanosine and lamivudine and the risk of myocardial infarction.
To read PDF, click here.
From D:A:D Steering Committee
On TheBodyPRO.com
- Increased Risk of Myocardial Infarction Associated With Abacavir and ddI (February 4, 2008)
From HIV i-Base
On TheBodyPRO.com
- HIV JournalView: Tenofovir + Didanosine: The Downfall of a Lovely Combination (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from TheBodyPRO.com
- ddI + Ribavirin May Cause Mitochondrial Toxicity (September 1, 2005)
In Journal of Acquired Immune Deficiency Syndromes
- HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From TheBodyPRO.com
- ddI + Tenofovir Combination Linked to Higher Pancreatitis Risk (October 2004)
Quick recap of a report in The Lancet.
In HIV Treatment ALERTS!, from The Center for AIDS
- Micronutrient Supplement Can Improve d4T-, ddI-Related Neuropathy, Study Says (March/April 2004)
In Positively Aware, from Test Positive Aware Network
- High Rate of Virologic Failure With Once-Daily ddI/3TC/TDF (November 2003)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
